Wednesday, October 10, 2018 The CCTG trial team, is happy to announce that the IND.211 trial has now officially closed. No further ethics approvals or follow-up data are required. The notification of permanent trial closure is posted on the CCTG website in the "Toolbox" and on the IND.211 trial page:https://www.ctg.queensu.ca/docs/trials/permanent_closure/I211-CTG-led-Final%20Letter_to_Cdn_sites.pdf Primary Objective: To evaluate the effect of reolysin in combination with either docetaxel or pemetrexed on the progression free survival of patients with advanced or metastatic non small cell lung cancer. Secondary Objectives: a) To determine the tolerability and toxicity of reolysin and docetaxel or pemetrexed when given in combination. b) To investigate additional potential measures of efficacy including: progression at 3 months, objective response rate and overall survival. c) To explore potential molecular factors predictive of response by assessment of archival tumour tissue and serial blood samples, including KRAS and EGFR status. The primary publication was distributed to sites on September 25, 2018. Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy Lung Cancer:120: 142 -148,2018. https://www.sciencedirect.com/science/article/pii/S0169500218302952
